Corrects paragraph 3 to say the drug showed reduction of 7.9 mmHg, not 11.7 mmHg, in mid-stage study
March 10 (Reuters) - Mineralys Therapeutics MLYS.O said on Monday its experimental drug met the main goal of lowering blood pressure in patients with uncontrolled or resistant hypertension in late- and mid- stage trials, sending its shares up about 43% before the bell.
In the late-stage study, the treatment called lorundrostat showed a placebo-adjusted reduction in systolic blood pressure by 9.1 mmHg (millimeters of mercury) at week six. The benefit was sustained through week 12, with a further reduction to 11.7 mmHg.
The drug also reduced systolic blood pressure by 7.9 mmHg in a mid-stage trial when compared to a placebo, the company said.
Lorundrostat inhibits the production of aldosterone, a hormone that can contribute to high blood pressure.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.